Seropositivity of Antibodies Against Hepatitis A Virus in Mashhad, Northeast of Iran, 2009: A Cross-Sectional Community-Based Study

Document Type : Original Article

Authors

Research Center for HIV/AIDS, HTLV and Viral Hepatitis, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad, IR Iran

10.30483/rijm.2015.118383

Abstract

Background: Hepatitis A Virus (HAV) is the most common cause of acute viral hepatitis worldwide, mostly in developing countries. Objectives: This population-based survey was performed to investigate HAV seroprevalence in Mashhad, northeast of Iran. Patients and Methods: A cross-sectional study was performed on 1563 randomly selected individuals from general population of Mashhad, Iran, between May and September 2009. Serum samples were tested for total anti-HAV antibodies using the Enzyme-Linked Immunosorbent Assay (ELISA) kit. Data was analyzed using SPSS ver. 18.0 by Chi-square and Student’s t-Tests. Results: Seroprevalence of HAV infection was 69.6% (95% CI: 67.3-71.9%) with no difference between males and females. Anti-HAV seropositivity increased with rising age from 9.4% in subjects younger than 5 years to 100.0% in individuals older than 65 years old (P < 0.001). Conclusions: As it was previously reported by the World Health Organization (WHO) on HAV infection in the country, this study revealed a high prevalence of HAV infection in Mashhad.

Keywords


  1. 1.Struchiner CJ, de Almeida LM, de Azevedo RS, Massad E. Hepatitis A incidence rate estimates from a pilot seroprevalence survey in Rio de Janeiro, Brazil. Int J Epidemiol. 1999;28(4):776–81.

    1. Tosun S, Ertan P, Kasirga E, Atman U. Changes in seroprevalence of hepatitis A in children and adolescents in Manisa, Turkey. Pediatr Int. 2004;46(6):669–72.
    2. Sagnelli E, Stroffolini T, Almasio P, Mele A, Coppola N, Ferrigno L, et al. Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study. J Viral Hepat. 2006;13(1):67–71.
    3. Krugman S. The Gordon Wilson Lecture. The ABC's of viral hepatitis. Trans Am Clin Climatol Assoc. 1992;103:145–56.
    4. Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine. 1992;10 Suppl 1:S15–7.
    5. Acharya SK, Batra Y, Bhatkal B, Ojha B, Kaur K, Hazari S, et al. Seroepidemiology of hepatitis A virus infection among school children in Delhi and north Indian patients with chronic liver disease: implications for HAV vaccination. J Gastroenterol Hepatol. 2003;18(7):822–7.
    6. Saab S, Lee C, Shpaner A, Ibrahim AB. Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepat. 2005;12(1):101–5.
    7. Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect. 2004;132(6):1005–22.
    8. Hendrickx G, Van Herck K, Vorsters A, Wiersma S, Shapiro C, Andrus JK, et al. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. J Viral Hepat. 2008;15 Suppl 2:1–15.
    9. Melnick JL. History and epidemiology of hepatitis A virus. J Infect Dis. 1995;171 Suppl 1:S2–8.
    10. Saffar MJ, Abedian O, Ajami A, Abedian F, Mirabi AM, Khalilian AR, et al. Age-specific seroprevalence of anti-hepatitis a antibody among 1-30 years old population of savadkuh, mazandaran, iran with literature review. Hepat Mon. 2012;12(5):326–32.
    11. Farajzadegan Z, Hoseini SG, Kelishadi R, Jamshidi F, Nokhodian Z, Noori R, et al. Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran. J Res Med Sci. 2014;19(Suppl 1):S56–63.
    12. Ataei B, Nokhodian Z, Javadi AA, Kasaeyan N, Farajzadegan Z, Shoaei P, et al. Seroepidemiology of hepatitis A virus infections in Over 6-years population in Isfahan–Iran: A community-based study. J Isfahan Med Sci. 2007;25(86):46–53.
    13. Hu MD, Schenzle D, Deinhardt F, Scheid R. Epidemiology of hepatitis A and B in the Shanghai area: prevalence of serum markers. Am J Epidemiol. 1984;120(3):404–13.
    14. Merat S, Rezvan H, Nouraie M, Abolghasemi H, Jamali R, AminiKafiabad S, et al. Seroprevalence and risk factors of hepatitis A virus infection in Iran: a population based study. Arch Iran Med. 2010;13(2):99–104.
    15. Taghavi SA, Hosseini Asl MK, Talebzadeh M, Eshraghian A. Seroprevalence study of hepatitis A virus in Fars province, southern Iran. Hepat Mon. 2011;11(4):285–8.
    16. Noroozi M, Moradi F, Hasanzadeh A. Seroprevalence of hepatitis A and hepatitis E in Qom province, 2011. Iran J Infect Dis Trop Med. 2012;17(4):19–23.
    17. Ramezani H, Bozorgi SH, Nooranipour M, Mostajeri A, KargarFard H, Molaverdikhani S, et al. Prevalence and risk factors of hepatitis A among blood donors in Qazvin, central Iran. Singapore Med J. 2011;52(2):107–12.
    18. Lu J, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, et al. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One. 2009;4(12). 20. Veldhuijzen IK, van Driel HF, Vos D, de Zwart O, van Doornum GJ, de Man RA, et al. Viral hepatitis in a multi-ethnic neighborhood in the Netherlands: results of a community-based study in a low prevalence country. Int J Infect Dis. 2009;13(1):e9–e13.
    19. Quaglio G, Ramadani N, Pattaro C, Cami A, Dentico P, Volpe A, et al. Prevalence and risk factors for viral hepatitis in the Kosovarian population: implications for health policy. J Med Virol. 2008;80(5):833–40.
    20. Ataei B, Javadi AA, Nokhodian Z, Kassaeian N, Shoaei P, Farajzadegan Z, et al. HAV in Isfahan province: a population-based study. Trop Gastroenterol. 2008;29(3):160–2.
    21. Vilibic-Cavlek T, Kucinar J, Ljubin-Sternak S, Kolaric B. Seroepidemiology of hepatitis a in the croatian population. Hepat Mon. 2011;11(12):997–9.
    22. Elikaei A, Sharifi Z, Shooshtari M, Hosseini M, Maroufi Y. Prevalence of HAV among healthy blood donors referring to Tehran transfusion center. Iran J Pub Health. 2008;37(4):126–30.
    23. Alian S, Ajami A, Ghasemian R, Yadegarinia D. Age-specific seroprevalence of hepatitis A in Sari, northern Islamic Republic of Iran. East Mediterr Health J. 2011;17(10):754–8.
    24. Campagna M, Siddu A, Meloni A, Basciu C, Ferrai L, Pettinau A, et al. Changing pattern of hepatitis a virus epidemiology in an area of high endemicity. Hepat Mon. 2012;12(6):382–5.
    25. Jacobsen KH. The Global Prevalence of Hepatitis A Virus Infection and Susceptibility: A Systematic Review. Geneva, Switzerland.: World Miri R et al. 4 Razavi Int J Med. 2015;3(2):e27082 Health Organization; 2009. Available from: http://whqlibdoc. who.int/hq/2010/WHO_IVB_10.01_eng.pdf. 28. Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev. 2006;28:101–11. 29. Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28(41):6653–7.
    26. Cech TV. Principles of water resources: history, development, management, and policy.USA: John Wiley & Sons; 2010.